FONT-SIZE Plus   Neg

Immunogen Inc. (IMGN) Is Up Sharply On Study Results

Immunogen Inc. (IMGN: Quote) announced Friday morning that Roche has announced positive results from its trastuzumab emtansine EMILIA Phase III trial. Trastuzumab emtansine consists of ImmunoGen's cancer-killing agent, DM1, attached to the HER2-targeting antibody, trastuzumab, and is in global development by Roche under an agreement between ImmunoGen and Genentech.

Immunogen has gapped open sharply higher Friday and is now up 1.76 at $15.50 on above average volume. The stock is now challenging the highs of the year, trading at an 8-month high.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Trade IMGN now with 
Follow RTT